Select Publications

Eastell R et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26(7):1051-7. Abstract

Forbes JF et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9(1):45-53. Abstract

Forbes JF et al. ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen (T) after treatment completion. San Antonio Breast Cancer Symposium 2007;Abstract 41.

Geyer CE et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733-43. Abstract

Gnant M et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. Proc ASCO 2008;Abstract LBA4.

Goss PE et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008a;26(12):1948-55. Abstract

Goss P et al. New clinical and experimental approaches for studying tumor dormancy: Does tumor dormancy offer a therapeutic target? APMIS 2008b;116(7-8):552-68. Abstract

Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract

Lin NU, Winer EP. Optimizing endocrine therapy for estrogen receptor-positive breast cancer: Treating the right patients for the right length of time. J Clin Oncol 2008;26(12):1919-21. Abstract

Lipton A et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008;113(1):193-201. Abstract

Lipton A et al. Survival in breast cancer patients with bone metastases and reductions in markers of bone resorption during zoledronic acid treatment. San Antonio Breast Cancer Symposium 2007;Poster 508.

O’Shaughnessy J et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Proc ASCO 2008;Abstract 1015.

Von Minckwitz G et al. Capecitabine vs capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). Proc ASCO 2008;Abstract 1025.

 

Home · Search

EDITOR
Neil Love, MD

INTERVIEWS

Paul E Goss, MD, PhD
- Select publications

Martine J Piccart-Gebhart, MD, PhD
- Select publications

TUMOR PANEL CASE DISCUSSION
- Select publications

INTERVIEWS (continued)

Erica L Mayer, MD, MPH
- Select publications

Maria Theodoulou, MD
- Select publications

 

Breast Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office